Lisa M. Demeter

University of North Carolina at Chapel Hill — United States

Immunology and Microbiology · Life Sciences

38h-index7.7kcitations97works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(79), HIV/AIDS drug development and treatment(73), HIV/AIDS Research and Interventions(55), Cervical Cancer and HPV Research(12), Pneumocystis jirovecii pneumonia detection and treatment(5)

Publications97 total

No Evidence for Decay of the Latent Reservoir in HIV‐1–Infected Patients Receiving Intensive Enfuvirtide‐Containing Antiretroviral Therapy
UNC Libraries·2020Open Access
HIV-1 viral load assays for resource-limited settings: Authors' reply [5]
UNC Libraries·2020Open Access
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
UNC Libraries·2020· 9 citedOpen Access
Combination Antiretroviral Treatment for Women Previously Treated Only in Pregnancy
JAIDS Journal of Acquired Immune Deficiency Syndromes·2013· 5 citedOpen Access
Discordant Associations Between SLCO1B1 521T→C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146
Therapeutic Drug Monitoring·2013· 15 citedOpen Access
Predictors of Residual Viraemia in Patients on Long-Term Suppressive Antiretroviral Therapy
Antiviral Therapy·2012· 24 citedOpen Access
Nonnucleoside Reverse Transcriptase Inhibitor-Resistant HIV Is Stimulated by Efavirenz during Early Stages of Infection
Journal of Virology·2011· 6 citedOpen Access
A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study
HIV Clinical Trials·2011· 8 citedOpen Access
Augmented HIV-Specific Interferon-Gamma Responses, But Impaired Lymphoproliferation During Interruption of Antiretroviral Treatment Initiated in Primary HIV Infection
JAIDS Journal of Acquired Immune Deficiency Syndromes·2011· 7 cited
Sequences in the U3 region of human immunodeficiency virus 1 improve efficiency of minus strand transfer in infected cells
Virology·2010· 22 cited
A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen
HIV Clinical Trials·2010· 17 citedOpen Access
Human Immunodeficiency Virus Type 1 Protease Inhibitor Drug-Resistant Mutants Give Discordant Results When Compared in Single-Cycle and Multiple-Cycle Fitness Assays
Journal of Clinical Microbiology·2010· 7 citedOpen Access
Prevalence of Primary Resistance at Baseline in Acutely and Recently Infected Subjects Enrolled in AIDS Clinical Trials Group Protocol 371
JAIDS Journal of Acquired Immune Deficiency Syndromes·2010· 6 cited
HIV‐1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy
Clinical Infectious Diseases·2010· 35 citedOpen Access
Reduced Fitness in Cell Culture of HIV-1 with Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Mutations Correlates with Relative Levels of Reverse Transcriptase Content and RNase H Activity in Virions
Journal of Virology·2010· 46 citedOpen Access
Quality Assessment for Therapeutic Drug Monitoring in AIDS Clinical Trials Group (ACTG 5146): A Multicenter Clinical Trial
Therapeutic Drug Monitoring·2010· 5 citedOpen Access
vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments
BMC Bioinformatics·2010· 12 citedOpen Access
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations
Virology·2010· 13 citedOpen Access
Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV‐1 Reverse Transcriptase
The Journal of Infectious Diseases·2010· 28 citedOpen Access
A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen
HIV Clinical Trials·2010· 12 cited
page 1 of 5Next →

Frequent Co-authors

Richard C. Reichman(14), Carrie Dykes(13), Margaret A. Fischl(7), Victoria A. Johnson(7), Daniel R. Kuritzkes(7), Douglas D. Richman(7), Robert A. Bambara(7), Scott M. Hammer(6), Martin Hirsch(5), Brian Conway(5), Bonaventura Clotet(5), Richard T. D’Aquila(5), William Bonnez(5), Gene D. Morse(5), Françoise Brun‐Vézinet(4), Peter Gerondelis(4), Robert W. Coombs(4), William W. Freimuth(4), Ronald J. Bosch(4), Mark H. Stoler(4)